Risk adjusted net present value: What is the current valuation of Caribou Biosciences’s CB-012?
CB-012 is a gene-modified cell therapy commercialized by Caribou Biosciences, with a leading Phase I program in Relapsed Acute Myeloid Leukemia.
CB-012 is a gene-modified cell therapy commercialized by Caribou Biosciences, with a leading Phase I program in Relapsed Acute Myeloid Leukemia.
What's Your Reaction?
